Faes Farma SA Total Assets

Latest as of June 2026: €1.44 Billion EUR ≈ $1.69 Billion USD

Faes Farma SA total assets. Based on the latest financial reports, Faes Farma SA (FAE) holds total assets worth €1.44 Billion EUR (≈ $1.69 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see FAE stock market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Faes Farma SA (2000–2025)

Total assets of Faes Farma SA from 2000 to 2025. This chart illustrates how Faes Farma SA's total assets have evolved over time, based on quarterly financial data. See latest Faes Farma SA stock price today for real-time trading data and today's change.

Faes Farma SA - Asset Composition Analysis

Faes Farma SA Total Assets Breakdown (December 2025)

Faes Farma SA total assets breakdown as of December 2025. Faes Farma SA's total assets of €1.44 Billion consist of 36.0% current assets and 64.1% non-current assets.

Asset Category Amount (EUR) % of Total Assets
Cash & Equivalents €0.00 8.7%
Accounts Receivable €167.30 Million 12.5%
Inventory €185.01 Million 13.8%
Property, Plant & Equipment €0.00 0.0%
Intangible Assets €199.40 Million 14.9%
Goodwill €258.48 Million 19.3%

Asset Composition Trend (2000–2025)

This chart illustrates how Faes Farma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Faes Farma SA (FAE) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Faes Farma SA's current assets represent 36.0% of total assets in 2025, an increase from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, up from 2.5% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 26.0% in 2000.
  • Asset Diversification: The largest asset category is goodwill at 19.3% of total assets.

Faes Farma SA Competitors by Total Assets

Key competitors of Faes Farma SA based on total assets are shown below.

Company Country Total Assets
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Galderma Group N
SW:GALD
Switzerland CHF12.88 Billion
Enzymatica publ AB
ST:ENZY
Sweden Skr149.24 Million
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥13.98 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd
SHG:600518
China CN¥13.68 Billion
Walvax BioTech
SHE:300142
China CN¥10.50 Billion

Faes Farma SA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.63 2.29 4.07
Quick Ratio 1.66 1.45 2.58
Cash Ratio 0.00 0.00 0.00
Working Capital €324.82 Million €238.45 Million €217.87 Million

Faes Farma SA - Advanced Valuation Insights

This section examines the relationship between Faes Farma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.78
Latest Market Cap to Assets Ratio 1.04
Asset Growth Rate (YoY) 57.3%
Total Assets €1.34 Billion
Market Capitalization $1.40 Billion USD

Valuation Analysis

Above Book Valuation: The market values Faes Farma SA's assets above their book value (1.04x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Faes Farma SA's assets grew by 57.3% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Faes Farma SA (2000–2025)

The table below shows the annual total assets of Faes Farma SA from 2000 to 2025.

Year Total Assets Change
2025-12-31 €1.34 Billion
≈ $1.57 Billion
+57.30%
2024-12-31 €853.08 Million
≈ $997.34 Million
+9.93%
2023-12-31 €776.03 Million
≈ $907.26 Million
+6.94%
2022-12-31 €725.67 Million
≈ $848.38 Million
+13.07%
2021-12-31 €641.76 Million
≈ $750.29 Million
+13.76%
2020-12-31 €564.15 Million
≈ $659.55 Million
+14.28%
2019-12-31 €493.67 Million
≈ $577.16 Million
+2.68%
2018-12-31 €480.80 Million
≈ $562.11 Million
+11.75%
2017-12-31 €430.24 Million
≈ $503.00 Million
+29.89%
2016-12-31 €331.22 Million
≈ $387.23 Million
+13.95%
2015-12-31 €290.68 Million
≈ $339.83 Million
+8.77%
2014-12-31 €267.23 Million
≈ $312.42 Million
-6.29%
2013-12-31 €285.16 Million
≈ $333.38 Million
-0.59%
2012-12-31 €286.84 Million
≈ $335.35 Million
-1.47%
2011-12-31 €291.12 Million
≈ $340.35 Million
-2.01%
2010-12-31 €297.10 Million
≈ $347.34 Million
+25.91%
2009-12-31 €235.97 Million
≈ $275.87 Million
-14.20%
2008-12-31 €275.01 Million
≈ $321.52 Million
+0.95%
2007-12-31 €272.43 Million
≈ $318.50 Million
+17.21%
2006-12-31 €232.43 Million
≈ $271.74 Million
+7.59%
2005-12-31 €216.04 Million
≈ $252.58 Million
+8.41%
2004-12-31 €199.29 Million
≈ $232.99 Million
+0.64%
2003-12-31 €198.01 Million
≈ $231.49 Million
+11.93%
2002-12-31 €176.91 Million
≈ $206.83 Million
-99.28%
2001-12-31 €24.57 Billion
≈ $28.73 Billion
+1.51%
2000-12-31 €24.21 Billion
≈ $28.30 Billion
--

About Faes Farma SA

MC:FAE Spain Drug Manufacturers - Specialty & Generic
Market Cap
$1.76 Billion
€1.50 Billion EUR
Market Cap Rank
#7228 Global
#63 in Spain
Share Price
€4.83
Change (1 day)
+1.05%
52-Week Range
€4.35 - €5.38
All Time High
€5.38
About

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants servic… Read more